Skip to content

Superiority of Rocuronium Reversed with Sugammadex for Overweight and Obese Patients Anesthesia: A Randomized Controlled Trial

Superiority of Rocuronium Reversed with Sugammadex for Overweight and Obese Patients Anesthesia: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800015044
Enrollment
Unknown
Registered
2018-03-03
Start date
2018-04-05
Completion date
Unknown
Last updated
2018-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight and Obese Patients Anesthesia

Interventions

experimental group A:rocuronium and sugamadex for the Laparoscopic anesthesia
experimental group D:rocuronium and sugamadex in the surgical anesthesia for obstructive sleep disorder syndrome
control group B:cisatracurium and neostigmine for the Laparoscopic anesthesia
control group C:rocuronium and neostigmine for the Laparoscopic anesthesia
control group E:cisatracurium and neostigmine in the surgical anesthesia for obstructive sleep disorder syndrome
control group F:rocuronium and neostigmine in the surgical anesthesia for obstructive sleep disorder syndrome

Sponsors

Department of Anesthesiology, Union hospital, Tongji medical college, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients undergoing laparoscopic surgery or surgery of obstructive sleep apnea hypopnea syndrome; 2. patients Body Mass Index=24.0kg/m2; 3. patients ASA physical status I~II.

Exclusion criteria

Exclusion criteria: 1. Drugs that have been used before surgery to influence the efficacy of muscle relaxants or neuromuscular transmission; 2. The site of muscle pine monitoring has a history of surgery or trauma in the recent month; 3. The history of hypertensive cerebral infarction, diabetes, heart disease, mental disease, and so on; 4. Anaphylaxis to non depolarizing muscle relaxants; 5. With the use of contraindications in neostigmine; 6. Suffering from a neuromuscular system or a history of small arthritis; 7. Formerly having alcoholism or drug abuse; 8. Abnormal indexes of liver and kidney function examination; 9. Preoperative examination of acid-base balance disorder; 10. Preoperative assessment of difficult airway.

Design outcomes

Primary

MeasureTime frame
Postoperative residual muscle relaxation rate;Evaluation of tracheal intubation condition;

Secondary

MeasureTime frame
Vital signs;Muscle relaxant effect;Postoperative adverse events;

Countries

China

Contacts

Public ContactShanglong Yao

Tongji Medical College of Huazhong University of Science and Technology

Ysltian@163.com+86 13886128437

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026